TissueGene-C articular cartilage regeneration

sturge8
sturge8 Member Posts: 164
edited 12. Mar 2013, 17:54 in Living with Arthritis archive
Articular regeneration by a novel injection therapy called TissueGene-C. It is being developed by the Koreans and is currently in a Phase II FDA-monitored study in Korea and USA. To read more have a look at this link from a current patient. Seems encouraging.

http://www.kneeguru.co.uk/KNEEtalk/index.php?topic=57918.0

Please can we not have a barrage of negative comments following this post. I am merely just highlighting something which sounds promising for OA sufferers.

Launch date for this product is 2013/14 Korea and USA 2015. However a lot could go pear-shaped between now & then which could mean it doesn't make it to market. Let's stay positive though.

Comments

  • helpline_team
    helpline_team Posts: 3,714
    edited 30. Nov -1, 00:00
    Hi everyone
    Have been asked to put up a short post about Research in OA. Well, Sturge8's post certainly highlights that the current research into treatments and interventions for those of us living with OA is truely global. Incidently there is another similar study into stem cell knee injections going on in a hospital research centre in Tehrain.
    It is good news to have hope in the future and to know there are literally hundreds of studies going on right now world wide looking at ways to treat, moderate the impacts and of course to regenerate our joints.
    Always be aware that some of the trials you see on the web are funded by private companies and investors and may be a long long way away before approval and availability. [as Sturge8 says]. Some of these trials are not of the standard that the FDA in the States and our own authorities will approve. Drugs and treatments approved by the FDA will not always get through the UK and the European approval.
    Usually most research which comes into fruition is undertaken by research centres like university hospitals where the companies funding the treatment are not allowed to influence the research and results. Then each have to go through the individual countries approval and licensing process who look at safety. In the UK each nation has its own prescribing approval authority [e.g. England & Wales NICE and the Scottish Medicines Consortium] Thats when we finally get to know if it will be on prescription. So a long process.
    But all research is another piece of hope for us all.
    Hope this helps ?
    Jo
    Jo Cumming
    Helplines Manager
  • stickywicket
    stickywicket Member Posts: 27,764
    edited 30. Nov -1, 00:00
    Thanks, Jo & Sturge. Mine's mostly RA but I have always found it comforting to know that there is research going on and therefore, eventually, new treatments on the horizon.
    If at first you don't succeed, then skydiving definitely isn't for you.
    Steven Wright
  • dorcas
    dorcas Member Posts: 3,516
    edited 30. Nov -1, 00:00
    Very interesting!

    It's good to hear what's going on by way of new treatments and therapies.
    especially as OA appears to be something of a 'cinderella' in arthritis research...

    So....thanks Sturge for raising awareness and Jo for the further info. :D:D

    Iris xx
  • frogmorton
    frogmorton Member Posts: 29,880
    edited 30. Nov -1, 00:00
    Thank you very much for this thread.

    An awful lot of people are/will be suffering from OA (some younger of course) so we should all be interested in this information.

    Great to hear not only from Sturge, who l know keeps up with the latest researc being done, but also from the helplines too.

    AS Dorcas says sometimes it does seem like OA is a bit of a cinderella as far as research into arthritis goes.

    Thanks very interesting.

    Toni xxx
  • sturge8
    sturge8 Member Posts: 164
    edited 30. Nov -1, 00:00
    Just thought i'd share a press release regarding TissueGene-C.

    http://www.tissuegene.com/news/releases.html

    If you get chance read the press release dated 11/14/2012

    I quote "We are very pleased with the clinical progress of TG‐C in both the US and Korea and look forward to reporting our Phase II data in 2013," stated Dr. Kwan Hee Lee, Chief Medical Officer of TissueGene.

    Looks like this year we can expect to hear how well it fairs in a clinical study.